There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility.
Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/
Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime.
It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent.
Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
It’s normal to have uric acid in your body, but too much can increase your risk for gout – an extremely painful form of inflammatory arthritis that often presents with other health issues, including kidney disease, heart disease, diabetes and permanent joint and tissue damage. Despite this, just 10 percent of gout sufferers are being properly treated – and more than one-third have not had their uric acid checked in the past five years.
To raise awareness about the need for timely treatment for gout – including regular monitoring of serum uric acid (sUA) levels – the Gout & Uric Acid Education Society (GUAES) has introduced a new “Go for Six” campaign. The campaign urges those who have or who are at risk for gout to get their sUA levels checked every six months, and to work with their doctor to determine a treatment plan for controlling gout and keeping sUA levels to a healthy 6 mg/dL or below.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7420351-gout-uric-acid-go-for-six-campaign/
With gout incidence on the rise, an increasing number of medical professionals, across multiple fields of practice, will continue to be exposed to patients who suffer from gout and are seeking an accurate diagnosis and treatment. However, despite the availability of the “Guidelines for the Management of Gout” by the American College of Rheumatology (ACR), there are many inconsistencies in how gout is diagnosed, treated and discussed by medical professionals. Conflicting messages and treatment recommendations can contribute to confusion, and even lack of compliance, on behalf of the patient – particularly when gout is connected with comorbid conditions, such as kidney disease, heart disease or diabetes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362551-gout-uric-acid-education-society-guaes-roundtable-consensus-paper/
At 37 years old, with a thriving concrete business, a wife and three young children, dying was the last thing on Travis Roberts’ mind. But after a doctor’s visit for a kidney stone, Roberts learned he had cholangiocarcinoma, a cancer of the bile duct. His survival rate was zero.
Roberts shared his story as part of Northwestern Mutual’s ongoing Client Stories series, which highlights the importance of financial security in the face of life’s most difficult circumstances.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7100753-northwestern-mutual-financial-security-cancer-diagnosis-disability-insurance/
This year, Bob Evans Farms is partnering with JDRF for the second year, with a goal of raising $100,000 for T1D research by selling JDRF’s signature paper sneakers in each of its 561 restaurants.
Starting today through March 19, guests can support the fight against T1D by making donations of their choice to JDRF at their local Bob Evans restaurant. Guests interested in making a contribution will receive one of JDRF’s paper sneakers to sign and display. In addition, on March 19, Bob Evans will host a national community fundraiser, donating 15 percent of sales to JDRF when guests present a fundraising flyer. To access and download the community fundraiser flyer, visit Bob Evans’ Curing Diabetes Facebook page.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65919-bob-evans-farms-fight-against-type-1-diabetes-t1d-jdrf-partnership
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
http://paininkidney.com/ksrr Did you know that you can pass kidney stones PAIN FREE and in a very short time by just using 2 grocery items in a special way? Check it out: http://paininkidney.com/ksrr
http://whatiskidneystones.com/ What is Kidney Stones? How can they be removed or prevented? Do you need doctor's help for this all the time all the time? The problem of what is kidney stones can be solved without the help of a doctor if water is used extensively in the body. For more details regarding kidney stones visit http://whatiskidneystones.com/
